Glycation and RAGE: Common links in the pathogenesis of microvascular and macrovascular complications of diabetes

Canadian Journal of Diabetes

Volumn 30, Issue 4, 2006, Pages 422-429

  Ramasamy, Ravichandran ^a   Yan, Shi Fang ^a   Schmidt, Ann Marie ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Advanced glycation; Macrovascular complications; Microvascular complications; Receptor; Signal transduction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; CALGRANULIN; IMMUNOGLOBULIN G; JANUS KINASE INHIBITOR; PERINDOPRIL; PROTEIN INHIBITOR; PROTEIN S 100; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BRAIN ATROPHY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GLYCATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOENCEPHALOPATHY; MICROALBUMINURIA; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROTEIN BINDING; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 33845675342     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(06)04007-X     Document Type: Article

References (43)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycoslyation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-234.
3. el Khoury J, Thomas CA, Loike JD, et al. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem. 1994;269:10197-10200.
4. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. Mol Med. 1995;1:634-646.
5. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 and 80K-H membrane proteins. Proc Natl Acad Sci U S A. 1996;93:11047-11052.
6. Ohgami N, Nagai R, Ikemoto M, et al. CD36 serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications. 2002;16:56-59.
7. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
8. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
9. ε (carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740-31749.
10. Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9:287-293.
11. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656-1666.
12. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685-691.
13. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2916-2924.
14. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354-360.
15. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637-668.
16. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem. 1987;262:16625-16635.
17. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
18. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
19. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003;108:1070-1077.
20. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2006;82:807-815.
21. Kosaki A, Hasegawa T, Kimura T, et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5423-5428.
22. Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24:2320-2325.
23. Katakami N, Matsuhisa M, Kaneto H, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005;28:2716-2721.
24. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2587-2593.
25. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363-2372.
26. Humpert PM, Kopf S, Djuric Z, et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care. 2006;29:1111-1113.
27. Mattock M, Morrish N, Viberti G, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
28. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium- dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
29. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238-243.
30. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123-1137.
31. Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004;53:166-172.
32. Tsuji H, Iehara N, Masegi T, et al. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun. 1998;245:583-588.
33. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261-268.
34. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest. 2004;114:1741-1751.
35. Toth C, Schmidt AM, Tuor UI, et al. Diabetes, leukoen cephalopathy and RAGE. Neurobiol Dis. 2006;23:445-461.
36. Goova M, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159:513-525.
37. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest. 2000;105:1117-1124.
38. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2001; 21:905-910.
39. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025-1031.
40. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827-2835.
41. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006;185:70-77.
42. Zhou Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003;107:2238-2243.
43. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959-972.